Direct-to-consumer platforms disrupt pharmaceutical distribution
The traditional pharmaceutical distribution model is shifting away from PBMs and insurance toward direct-to-consumer platforms that offer lower cash prices.
The argument
The guest argued that massive consumer pressure and platforms like Hims & Hers have forced drug companies to bypass traditional intermediaries. This structural shift was highlighted by the price of GLP-1 weight loss medications dropping by 80% in 18 months to a cash price of $150 to $200.
The thesis, stress-tested
✓ What validates it
- ✓Further price reductions in blockbuster drugs distributed via DTC channels
- ✓Increased volume of direct-to-consumer prescriptions bypassing insurance
▸ Risks discussed
- ▸Dependence on partnerships with drug manufacturers for supply and pricing
- ▸Potential regulatory changes in compounding and direct-to-consumer drug sales
Hear it yourself
"And thanks to the drug companies, they actually agreed to bring them down from the thousands of dollars to a 150 to $200 cash break prices. I mean, that is, like, completely transformative. It's not something that's really happened in pharmaceutical history that the blockbuster drug of the century gets cut by 80% in eighteen months."
00:00 / 00:19
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE